Progress in the Development of a Cervical Cancer Vaccine

References

• BoschFXManosMMMunozNPrevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study GroupJ Natl Cancer Inst1995877968027791229
   PubMed Web of Science ®Google Scholar
• BreitburdFKirnbauerRHubbertNLImmunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infectionJ Virol1995693959637745754
   PubMed Web of Science ®Google Scholar
• ChandrachudLMGrindlayGJMcGarvieGMVaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4Virology199521120487544045
   PubMed Web of Science ®Google Scholar
• Corona GutierrezCMTinocoANavarroTTherapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirusHum Gene Ther2004154213115144573
   PubMed Web of Science ®Google Scholar
• CuzickJSzarewskiACubieHManagement of women who test positive for high-risk types of human papillomavirus: the HART studyLancet20033621871614667741
   PubMed Web of Science ®Google Scholar
• DavidsonEJBoswellCMSehrPImmunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteinsCancer Res20036360324114522932
   PubMed Web of Science ®Google Scholar
• DavidsonEJFaulknerRLSehrPEffect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)Vaccine2004222722915246603
   PubMed Web of Science ®Google Scholar
• de JongAO’NeillTKhanAYEnhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccineVaccine20022034566412297390
   PubMed Web of Science ®Google Scholar
• [DOH] Department of HealthJoint committee on vaccination and immunisation [online]2005 Accessed 3 December 2005. URL: http://www.advisorybodies.doh.gov.uk/JCVI/index.htm
   Google Scholar
• DoorbarJThe papillomavirus life cycleJ Clin Virol200532Suppl 1S71515753007
   PubMed Web of Science ®Google Scholar
• DubinGColauBZahafTCross-protection against persistent HPV infection, abnormal cytology and CIN associated with HPV-16 and 18 related HPV types by a HPV 16/18 L1 virus-like particle vaccine200522nd International Papillomavirus ConferenceApril 30 – May 6Vancouver, Canada32
   Google Scholar
• EinsteinMHKadishASBurkRDHeat shock protein (HSP)-based immunotherapy (HSPE7) for treatment of CINIII (NCI 5850, NYGOG)Gynecol Oncol20059691213
   Google Scholar
• EmbersMEBudgeonLRPickelMProtective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid proteinJ Virol200276979880512208958
   PubMed Web of Science ®Google Scholar
• FerlayJBrayFPisaniPGLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.02001Lyon, FranceIARC Pr (IARC Cancer Base No. 5)
   Google Scholar
• FerraraANonnMSehrPDendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patientsJ Cancer Res Clin Oncol20031295213012898233
   PubMed Web of Science ®Google Scholar
• FrazerIHPrevention of cervical cancer through papillomavirus vaccinationNat Rev Immunol20044465414704767
   PubMed Web of Science ®Google Scholar
• FrazerIHQuinnMNicklinJLPhase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasiaVaccine2004231728115531034
   PubMed Web of Science ®Google Scholar
• GambhiraRBossisIViscidiRCross-neutralising antibody response of healthy volunteers vaccinated with human papillomavirus (HPV) 16 minor capsid protein L2200522nd International Papillomavirus ConferenceApril 30 – May 6Vancouver, Canada227
   Google Scholar
• GarciaFPetryKUMuderspachLZYC101a for treatment of high grade intraepithelial neoplasia. A randomised controlled trialObstet Gynecol20041033172614754702
   PubMed Web of Science ®Google Scholar
• GarridoFRuiz-cabelloFCabreraTImplications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunol Today19971889959057360
   PubMedGoogle Scholar
• GhimSJJensonABSchlegelRHPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virionsVirology1992190548521382345
   PubMed Web of Science ®Google Scholar
• GoldieSJKohliMGrimaDProjected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccineJ Natl Cancer Inst2004966041515100338
   PubMed Web of Science ®Google Scholar
• HallezSSimonPMaudouxFPhase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasiaCancer Immunol Immunother2004536425014985860
   PubMed Web of Science ®Google Scholar
• HarperDMFrancoELWheelerCEfficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialLancet200436417576515541448
   PubMed Web of Science ®Google Scholar
• [IARC] International Agency for Research on CancerCervix cancer screening2005Lyon, FranceIARC Pr
   Google Scholar
• KadishASEinsteinMHVaccine strategies for human papillomavirus-associated cancersCurr Opin Oncol2005174566116093795
   PubMed Web of Science ®Google Scholar
• KaufmannAMSternPLRankinEMSafety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancerClin Cancer Res2002836768512473576
   PubMed Web of Science ®Google Scholar
• KirnbauerRBooyFChengNPapillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenicProc Natl Acad Sci U S A1992891218041334560
   PubMed Web of Science ®Google Scholar
• KirnbauerRChandrachudLMO’NeilBWVirus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunizationVirology199621937448623552
   PubMed Web of Science ®Google Scholar
• KitchenerHAlmonteMWheelerPThe ARTISTIC trial of HPV testing in primary cervical screening: methods and baseline data200522nd International Papillomavirus ConferenceApril 30 – May 6Vancouver, Canada22
   Google Scholar
• KoutskyLAAultKAWheelerCMA controlled trial of a human papillomavirus type 16 vaccineN Engl J Med200234716455112444178
   PubMed Web of Science ®Google Scholar
• MahdaviAMonkBJVaccines against human papillomavirus and cervical cancer: promises and challengesOncologist2005105283816079320
   PubMed Web of Science ®Google Scholar
• MaoCKoutskyLAultKAEfficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasiaObstet Gynecol2006107182716394035
   PubMed Web of Science ®Google Scholar
• MarkowitzLDunneEGilsdorfJDevelopment of recommendations for HPV vaccine use in the United States200522nd International Papillomavirus ConferenceApril 30 – May 6Vancouver, Canada35
   Google Scholar
• Martin-HirschPLParaskevaidisEKitchenerHSurgery for cervical intraepithelial neoplasiaCochrane Database Syst Rev1999Issue 3
   Google Scholar
• MuderspachLWilczynskiSRomanLA phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positiveClin Cancer Res2000634061610999722
   PubMed Web of Science ®Google Scholar
• MunozNBoschFXCastellsagueXAgainst which human papillomavirus types shall we vaccinate and screen? The international perspectiveInt J Cancer20041112788515197783
   PubMed Web of Science ®Google Scholar
• [NCI] National Cancer InstituteClinical trials [online]2005 Accessed 22 November 2005. URL: http://www.cancer.gov/clinicaltrials
   Google Scholar
• [NHSCSP] NHS Cervical Screening ProgrammeColposcopy and programme management: guidelines for the NHS Cervical Screening Programme2004Sheffield, UKNHSCSP Publication No. 20
   Google Scholar
• [ONS] Office for National StatisticsCancer registrations in England 2003 National Statistics [online]2005a Accessed 3 December 2005. URL: http://www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D9096.xls
   Google Scholar
• [ONS] Office for National StatisticsUpdate to cancer trends in England and Wales 1950–1999 National statistics [online]2005b Accessed 3 December 2005. URL: http://www.statistics.gov.uk/downloads/theme_health/CancerTrendsUpdates.pdf
   Google Scholar
• ParkinDMWorld burden of infection-associated cancers200522nd International Papillomavirus ConferenceApril 30 – May 6Vancouver, Canada10
   Google Scholar
• ParkinDMBrayFFerlayJGlobal cancer statistics 2002CA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• PastranaDVGambhiraRBuckCBCross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2Virology20053373657215885736
   PubMed Web of Science ®Google Scholar
• PetoJGilhamCFletcherOThe cervical cancer epidemic that screening has prevented in the UKLancet20043642495615262102
   PubMed Web of Science ®Google Scholar
• PrendivilleWCullimoreJNormanSLarge loop excision of the transformation zone (LLETZ). A new method of management for women with cervical intraepithelial neoplasiaBr J Obstet Gynaecol1989961054602804007
   PubMedGoogle Scholar
• RessingMEvan DrielWJBrandtRMDetection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinomaJ Immunother2000232556610746552
   PubMed Web of Science ®Google Scholar
• RodenRBGreenstoneHLKirnbauerRIn vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotypeJ Virol1996705875838709207
   PubMed Web of Science ®Google Scholar
• RoseRCReichmanRCBonnezWHuman papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human seraJ Gen Virol199475Pt 8207598046412
   PubMed Web of Science ®Google Scholar
• SkjeldestadFEProphylactic quadrivalent human papillomavirus (HPV) (Types 6,11,16,18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk200543rd Annual Meeting of IDSAOctober 6–9San Francisco, USA53
   Google Scholar
• SmithKLTristramAGallagherKMEpitope specificity and longevity of a vaccine-induced human T cell response against HPV18Int Immunol2005171677615623547
   PubMed Web of Science ®Google Scholar
• SmythLJVan PoelgeestMIDavidsonEJImmunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccinationClin Cancer Res20041029546115131030
   PubMed Web of Science ®Google Scholar
• SternPLFaulknerRVeranesEKitchenerHCThe role of human papillomavirus vaccines in cervical neoplasiaHuman papillomavirus: best practice in clinical obstetrics and gynaecology2001LondonBalliere Tindall78399
   Google Scholar
• SternPLImmune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccinationJ Clin Virol200532Suppl 1S72S8115753015
   PubMed Web of Science ®Google Scholar
• SuzichJAGhimSJPalmer-HillFJSystemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomasProc Natl Acad Sci U S A1995921155378524802
   PubMed Web of Science ®Google Scholar
• VambutasADeVotiJNouriMTherapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus modelVaccine20052352718016054734
   PubMed Web of Science ®Google Scholar
• VillaLLCostaRLPettaCAProphylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLancet Oncol20056271815863374
   PubMed Web of Science ®Google Scholar
• WalboomersJMJacobsMVManosMMHuman papillomavirus is a necessary cause of invasive cervical cancer worldwideJ Pathol1999189121910451482
   PubMed Web of Science ®Google Scholar
• WallerJMcCafferyKForrestSAwareness of human papillomavirus among women attending a well woman clinicSex Transm Infect200379320212902585
   PubMed Web of Science ®Google Scholar
• WoodJMLevandowskiRAThe influenza vaccine licensing processVaccine2003211786812686095
   PubMed Web of Science ®Google Scholar
• ZhouJSunXYStenzelDJExpression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particlesVirology199118525171656586
   PubMed Web of Science ®Google Scholar
• zur HausenHde VilliersEMGissmannLPapillomavirus infections and human genital cancerGynecol Oncol198112S12486273261
   PubMed Web of Science ®Google Scholar
• ZwavelingSFerreira MotaSCNoutaJEstablished human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptidesJ Immunol2002169350812077264
   PubMed Web of Science ®Google Scholar